deltatrials
Completed NCT01016444

Acute Asthma Responsiveness and B2 Adrenergic Receptors Polymorphisms

β2AR Polymorphisms and Albuterol Responsiveness in Acute Asthma

Sponsor: GlaxoSmithKline

Conditions Acute Asthma
Updated 11 times since 2017 Last updated: Aug 26, 2021 Started: Dec 31, 2009 Primary completion: Jul 29, 2011 Completion: Jul 29, 2011

Listed as NCT01016444, this observational or N/A phase trial focuses on Acute Asthma and remains completed. Sponsored by GlaxoSmithKline, it has been updated 11 times since 2009, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Change History

11 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed

  2. Jul 2024 — Sep 2024 [monthly]

    Completed

  3. Dec 2021 — Jul 2024 [monthly]

    Completed

  4. Oct 2021 — Dec 2021 [monthly]

    Completed

    Status: Unknown Status → Completed

  5. Jan 2021 — Oct 2021 [monthly]

    Unknown Status

▶ Show 6 earlier versions

  1. Nov 2020 — Jan 2021 [monthly]

    Unknown Status

  2. Jun 2018 — Nov 2020 [monthly]

    Unknown Status

  3. May 2018 — Jun 2018 [monthly]

    Unknown Status

  4. Apr 2018 — May 2018 [monthly]

    Unknown Status

    Phase: NA → None

  5. Aug 2017 — Apr 2018 [monthly]

    Unknown Status NA

  6. Jan 2017 — Aug 2017 [monthly]

    Unknown Status NA

    First recorded

Dec 2009

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • GlaxoSmithKline
  • MetroHealth Medical Center
Data source: MetroHealth Medical Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

  • • Cleveland, United States